Mohanad Naji Sahib

Dr. Mohanad Naji Sahib

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2012 in Patient Preference and Adherence
Verified
Journal Article
Open access
SAShaymaa Abdalwahed Abdulameer
Shaymaa Abdalwahed Abdulameer
SSSyed Azhar Syed Sulaiman
Syed Azhar Syed Sulaiman
AHAzmi Hassali
Azmi Hassali
KSKaruppiah Subramaniam
Karuppiah Subramaniam
MSMohanad Naji Sahib
Mohanad Naji Sahib
Peer reviewed article authored by (Abdulameer SA, Syed Sulaiman SA, Hassali MA, Subramaniam K, Sahib MN). Read article or submit your manuscript for publishing.

1 October 2011 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
MSMohanad Naji Sahib
Mohanad Naji Sahib
YDYusrida Darwis
Yusrida Darwis
KPKok Khiang Peh
Kok Khiang Peh
SAShaymaa Abdalwahed Abdulameer
Shaymaa Abdalwahed Abdulameer
YTYvonne Tze Fung Tan
Yvonne Tze Fung Tan
Background: Inhaled corticosteroids provide unique systems for local treatment of asthma or chronic obstructive pulmonary disease. However, the use of poorly soluble drugs for nebulization has been inadequate, and many patients rely on large doses to achieve optimal control of their disease. Theoretically, nanotechnology with a sustained-release formulation may provide a favorable therapeutic index. The aim of this study was to determine the feasibility of using sterically stabilized phospholipid nanomicelles of budesonide for pulmonary delivery via nebulization. Methods: PEG5000-DSPE polymeric micelles containing budesonide (BUD-SSMs) were prepared by the coprecipitation and reconstitution method, and the physicochemical and pharmacodynamic characteristics of BUD-SSMs were investigated. Results: The optimal concentration of solubilized budesonide at 5 mM PEG5000-DSPE was 605.71 ± 6.38 µg/mL, with a single-sized peak population determined by photon correlation spectroscopy and a particle size distribution of 21.51 ± 1.5 nm. The zeta potential of BUD-SSMs was -28.43 ± 1.98 mV. The percent entrapment efficiency, percent yield, and percent drug loading of the lyophilized formulations were 100.13% ± 1.09%, 97.98% ± 1.95%, and 2.01% ± 0.02%, respectively. Budesonide was found to be amorphous by differential scanning calorimetry, and had no chemical interaction with PEGylated polymer according to Fourier transform infrared spectroscopy. Transmission electron microscopic images of BUD-SSMs revealed spherical nanoparticles. BUD-SSMs exhibited prolonged dissolution behavior compared with Pulmicort Respules® (P , 0.05). Aerodynamic characteristics indicated significantly higher deposition in the lungs compared with Pulmicort Respules®. The mass median aerodynamic, geometric standard deviation, percent emitted dose, and the fine particle fraction were 2.83 ± 0.08 µm, 2.33 ± 0.04 µm, 59.13% ± 0.19%, and 52.31% ± 0.25%, respectively. Intratracheal administration of BUD-SSMs 23 hours before challenge (1 mg/kg) in an asthmatic/chronic obstructive pulmonary disease rat model led to a significant reduction in inflammatory cell counts (76.94 ± 5.11) in bronchoalveolar lavage fluid compared with administration of Pulmicort Respules® (25.06 ± 6.91). Conclusion: The BUD-SSMs system might be advantageous for asthma or chronic obstructive pulmonary disease and other inflammatory airway diseases.

1 February 2012 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
MSMohanad Naji Sahib
Mohanad Naji Sahib
YDYusrida Darwis
Yusrida Darwis
KPKok Khiang Peh
Kok Khiang Peh
SAShaymaa Abdalwahed Abdulameer
Shaymaa Abdalwahed Abdulameer
YTYvonne Tze Fung Tan
Yvonne Tze Fung Tan
Background: The local treatment of lung disorders such as asthma and chronic obstructive pulmonary disease via pulmonary drug delivery offers many advantages over oral or intravenous routes of administration. This is because direct deposition of a drug at the diseased site increases local drug concentrations, which improves the pulmonary receptor occupancy and reduces the overall dose required, therefore reducing the side effects that result from high drug doses. From a clinical point of view, although jet nebulizers have been used for aerosol delivery of water-soluble compounds and micronized suspensions, their use with hydrophobic drugs has been inadequate. Aim: To evaluate the feasibility of sterically stabilized phospholipid nanomicelles (SSMs) loaded with beclomethasone dipropionate (BDP) as a carrier for pulmonary delivery. Methods: 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 5000) polymeric micelles containing BDP (BDP-SSMs) were prepared by the coprecipitation and reconstitution method, and the physicochemical and in vitro characteristics of BDP-SSMs were investigated. Results: BDP-SSMs were successfully prepared with a content uniformity and reproducibility suitable for pulmonary administration. The maximum solubility of BDP in SSMs was approximately 1300 times its actual solubility. The particle size and zeta potential of BDP-SSMs were 19.89 ± 0.67 nm and -28.03 ± 2.05 mV, respectively. The SSMs system slowed down the release of BDP and all of the aerodynamic values of the aerosolized rehydrated BDP-SSMs were not only acceptable but indicated a significant level of deposition in the lungs. Conclusion: The SSM system might be an effective way of improving the therapeutic index of nebulized, poorly soluble corticosteroids.

25 April 2018 in The Open Rheumatology Journal
Verified
Journal Article
Open access
PDF file
SAShaymaa Abdalwahed Abdulameer
Shaymaa Abdalwahed Abdulameer
MSMohanad Naji Sahib
Mohanad Naji Sahib
SSSyed Azhar Syed Sulaiman
Syed Azhar Syed Sulaiman
Background: Type 2 Diabetes Mellitus (T2DM) and osteoporosis are both chronic conditions and the relationship between them is complex.Objective: The aims of this study were to assess the prevalence of Low Bone Mineral density (LBMD,i.e., osteopenia and osteoporosis), as well as, the difference and associations between Quantitative Ultrasound Scan (QUS) parameters with socio-demographic data and clinical related data among T2DM in Penang, Malaysia.Method: An observational, cross-sectional study with a convenient sample of 450 T2DM patients were recruited from the outpatient diabetes clinic at Hospital Pulau Pinang (HPP) to measure Bone Mineral Density (BMD) at the heel bone using QUS. In addition, a self-reported structured questionnaire about the socio-demographic data and osteoporosis risk factors were collected. Moreover, the study included the retrospective collection of clinical data from patients’ medical records.Results: The mean value of T-score for normal BMD, osteopenic and osteoporotic patients’ were (-0.41±0.44), (-1.65±0.39) and (-2.76±0.27), respectively. According to QUS measurements, more than three quarters of T2DM patients (82%) were at high risk of abnormal BMD. The results showed that QUS scores were significantly associated with age, gender, menopausal duration, educational level and diabetic related data. Moreover, the QUS parameters and T-scores demonstrated significant negative correlation with age, menopausal duration, diabetic duration and glycaemic control, as well as, a positive correlation with body mass index and waist to hip ratio. The current study revealed that none of the cardiovascular disease risk factors appear to influence the prevalence of low BMD among T2DM Malaysian patients.Conclusion: The study findings revealed that the assessment of T2DM patients’ bone health and related factor are essential and future educational programs are crucial to improve osteoporosis management.

1 January 2012 in Patient Preference and Adherence
Verified
Journal Article
Open access
SAShaymaa Abdalwahed Abdulameer
Shaymaa Abdalwahed Abdulameer
MSMohanad Naji Sahib
Mohanad Naji Sahib
NANoorizan Abd Aziz
Noorizan Abd Aziz
YHYahaya Hassan
Yahaya Hassan
HAHadeer Akram Abdul Alrazzaq
Hadeer Akram Abdul Alrazzaq
OIOmar Ismail
Omar Ismail
Peer reviewed article authored by (Abdulameer SA, Sahib MN, Abd Aziz N, Hassan Y, Abdul AlRazzaq HA, Ismail O). Read article or submit your manuscript for publishing.

3 August 2022 in Drug Development and Industrial Pharmacy
Verified
Journal Article
Closed access
MMMasar Basim Mohsin Mohamed
Masar Basim Mohsin Mohamed
LDLina Dahabiyeh
Lina Dahabiyeh
MSMohanad Naji Sahib
Mohanad Naji Sahib
The low molecular weight organogels are interesting carriers for pharmaceutical compounds. However, their uses are limited due to the toxicity burden of the organic solvent used. Hence, this study ...